Here's the link to the 'program': http://www.nae.edu/Programs/FOE/GAFOE/2010GAFOE/16809/17868.aspx
Note 4/24 @ 9AM for Rahul.
Also note that there's a whole separate set of presentations on similar topic the day before.
And here's the link to the overview of his presentation:
Didn't seem like anything new until I saw this sentence: "We present a possible solution to this problem using engineering concepts and provide a case study of our solution for low cost manufacturing of pandemic influenza vaccines"
The 'CASE STUDY' part is what jumped out at me...
What do we think they'll be using as a CASE STUDY? Maybe Xcellerex for production of the vaccines used in the Mexico trials?
Totally thinking out loud on my part, but have no real clue.
I would expect the 'case study' that would be presented would be when NVAX was the first to produce a s AH1N1 flu vaccine last April. That is when NVAX produced a vaccine to test in about 8 weeks using only virus data from the CDC.
The world has been throwing crap in NVAX's face ever since. Kinda weird, really.
"Two speakers are contributing to cutting-edge technologies for the
rapid production of flu vaccines and will highlight two aspects of flu vaccine production:
Dr. Ulrich Valley, Novartis, Germany, on cell-culture based flu vaccine production, and
Dr. Rahul Singhvi, Novavax, on a novel VLP-based flu vaccine in an insect cell system."
New Technologies in VaccineManufacturing and their Impact on a Growing Global
"innovation in vaccine bioprocess and manufacturing is changing
at an increased rate. As shown recently, a small vaccine developer has partnered with a
large technology provider to advance a pandemic flu vaccine manufacturing solution. In
this model, the vaccine developer is leveraging the technology partner’s expertise with
flexible manufacturing, bioprocess solutions, and design expertise—along with the
developer’s technology and manufacturing platform. This creates a partnership that
leverages each organization’s strengths to establish manufacturing infrastructure that is
cheaper, faster to construct, and more flexible than traditional facilities."
how does he use the mexican trials/production as a case study when we don't have results?
or do we?
screens picking up mass flights of bogies, jap zeroes, cylon raiders, death stars, klingon cruisers headed my way
shields up, engage cloaking devise, phone torpedoes and phasers on kill, fire on my command
whew, got a lot of sci fi in this post
oh one more
danger, dange 6vreb, danger
My assumption is that the vaccine for the CLINICAL TRIALS was done using the process to be discussed... NOT assuming there's full fledged vaccine production going on, just that produced for the trials... OR, do we know that those vaccines were produced in Rockville, MD?
why mention major charitable contributions?
this looks like an engineering forum almost
this is the presentation that robinson would give if he were still there
u of tennessee
"the other ut" wearing creamsicle orange
good catch scottie
Significant attention is now being paid to
understand and improve the situation with new resources being made available through
major charitable contributions.